AGS 67E

Drug Profile

AGS 67E

Alternative Names: AGS67E

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agensys
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Hairy cell leukaemia; Lymphoid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 11 Dec 2017 AGS 67E is still in phase I trials for Lymphoid leukaemia, Hairy cell leukaemia, Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA and Canada (Astellas Pharma pipeline, December 2017)
  • 30 Nov 2017 Agensys suspends patient enrolment in a phase I trials due to business decision by sponsor for Acute myeloid leukaemia (Second-line therapy or greater) in USA, Canada (IV) (NCT02610062)
  • 30 Nov 2017 Agensys suspends patient enrolment in a phase I trials due to business decision by sponsor for Lymphoid leukaemia, Hairy cell leukaemia, Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA and Canada (IV) (NCT02175433)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top